Literature DB >> 30852840

Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials.

Shailesh Advani1,2, Scott Kopetz2.   

Abstract

Metastatic colorectal cancer (mCRC) continues to show poor outcomes, with many patients exhausting effective standard-of-care therapy. To explore the current landscape of clinical trials for mCRC, we reviewed over 600 clinical trials that are currently ongoing for mCRC patients. Immunotherapeutic agents form approximately 39% (includes monoclonal antibodies, viruses, vaccines, and immunomodulators) of all agents and targeted therapy forms 45% (tyrosine kinase inhibitors, epigenetic modulators, and others) of all agents being investigated for mCRC.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  clinical trials; colorectal cancer; immunotherapy; metastatic; targeted therapy

Mesh：

Substances：

Year:  2019        PMID： 30852840     DOI： 10.1002/jso.25441

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  6 in total

1.  Effects of Chemotherapy for Metastatic Colorectal Cancer on the TGF-β Signaling and Related miRNAs hsa-miR-17-5p, hsa-miR-21-5p and hsa-miR-93-5p.

Authors:  Jovana Despotovic; Sandra Dragicevic; Aleksandra Nikolic
Journal:  Cell Biochem Biophys       Date:  2021-04-07       Impact factor: 2.194

2.  GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer.

Authors:  Amanda N Lisby; John C Flickinger; Babar Bashir; Megan Weindorfer; Sanjna Shelukar; Madison Crutcher; Adam E Snook; Scott A Waldman
Journal:  Expert Rev Precis Med Drug Dev       Date:  2021-02-02

Review 3.  Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer.

Authors:  Daniel Sur; Andrei Havasi; Calin Cainap; Gabriel Samasca; Claudia Burz; Ovidiu Balacescu; Iulia Lupan; Diana Deleanu
Journal:  J Clin Med       Date:  2020-01-09       Impact factor: 4.241

4.  Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53.

Authors:  Patrizia Malkomes; Ilaria Lunger; Elsie Oppermann; Khalil Abou-El-Ardat; Thomas Oellerich; Stefan Günther; Can Canbulat; Sabrina Bothur; Frank Schnütgen; Weijia Yu; Susanne Wingert; Nadine Haetscher; Claudia Catapano; Marina S Dietz; Mike Heilemann; Hans-Michael Kvasnicka; Katharina Holzer; Hubert Serve; Wolf Otto Bechstein; Michael A Rieger
Journal:  Oncogene       Date:  2021-06-08       Impact factor: 9.867

5.  Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [177Lu]Lu-PP-F11N.

Authors:  Michal Grzmil; Yun Qin; Carina Schleuniger; Stephan Frank; Stefan Imobersteg; Alain Blanc; Martin Spillmann; Philipp Berger; Roger Schibli; Martin Behe
Journal:  Theranostics       Date:  2020-08-29       Impact factor: 11.556

6.  Efficacy and safety of ramucirumab treatment in patients with advanced colorectal cancer: A protocol for systematic review and meta analysis.

Authors:  Man Ju; Honggang Cheng; Kai Qu; Xiangqian Lu
Journal:  Medicine (Baltimore)       Date:  2020-06-12       Impact factor: 1.817
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.